Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu) Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia Leukemia (2015) 29, 988-991; doi:10.1038/leu. 2014.327 It is postulated that disease relapse in patients with acute myeloid leukaemia (AML) is consequent upon chemoresistance within leukaemic stem/progenitor cell (LSC) populations from which bulk blasts arise. 1 In adults with high-risk AML, allogeneic haematopoietic cell transplantation (HCT) has become a central component of the treatment algorithm to overcome this chemoresistance, as it delivers maximal anti-leukaemic activity through both dose intensification and by the genesis of a potent graft-versus-leukaemia (GVL) effect. [2] [3] [4] However, relapse still occurs in a significant proportion of allografted patients and now represents the major cause of treatment failure, particularly with reduced intensity conditioning (RIC) regimens. 5 Although minimal residual disease (MRD) from the bulk leukaemic population is known to be prognostic, more accurate predictors of relapse risk might be developed from detection of putative LSC populations pre-or post transplant. However, to date an association between LSC and transplant outcome remains uncertain.
Xenotransplantation assays, which have characterised the leukaemic propagating functional properties of LSCs, cannot be applied as a routine clinical assay to track LSC residual disease in AML patients. As well as monitoring MRD from bulk leukaemic blasts, 6 multiparameter flow cytometry (MFC) assays can be used to quantitate candidate immunophenotypic haematopoietic stem/progenitor populations characterised as enriched for LSC activity. 7, 8 We report the first study to evaluate an immunophenotypic LSC assay as a biomarker for outcome in allografted AML patients, performed in parallel with standard MFC-MRD monitoring (using conventional leukaemic aberrant immunophenotypes) and chimerism studies for pre-and post-HCT time points in 101 adults undergoing HCT for high-risk AML or myelodysplasia. Our cohort included predominantly older patients, many of whom were allografted using a RIC regimen (RIC = 73; myeloablative conditioning, MAC = 28). The results are thus relevant to similar patient populations in many adult transplant centres, as RIC-HCT is increasingly used for older patients with AML/high-risk myelodysplasia.
Immunophenotypic LSC (MFC-LSC) were monitored by quantitating the lymphoid-primed multi-potential progenitor-like (LMPPlike) stem/progenitor compartment. This assay does not require an aberrant LSC profile to be identified at presentation, but instead measures an abnormally expanded immunophenotypic CD34+ population previously functionally characterised to be LSCcontaining, 7,9 with a detection threshold of 0.02% of total nucleated bone marrow cells (validated in Craddock et al. 9 and further validated for this study, Supplementary Figure 2B ). Detection of these MFC-LSC antedated morphological relapse in a prior cohort of patients post chemotherapy 9 (further example, Supplementary Figure 3 ). Detailed methods for this study are available in Supplementary Information.
The pre-transplant demographics of all 101 patients stratified by MFC-MRD and MFC-LSC status pre-and post HCT are summarised in Table 1 . In the overall cohort, there were 36 deaths, 25 relapses, 17 non-relapse mortality (NRM) with a median follow-up among survivors of 18 months (range 7-44 months). Twenty-eight patients had acute graft-versus-host disease and 10 patients received donor lymphocyte infusions (DLIs).
Pre-HCT, MFC-LSC-positivity was less frequent (21%, 15/72) compared with MFC-MRD-positivity (50%, 33/66) in assessable patients. However, MFC-LSC were detected in 10% of assessable MFC-MRD-negative patients and in 17% of patients who could not be analysed for MFC-MRD. Thus MFC-LSC monitoring by this assay identifies a distinct subgroup of patients including some who could not be monitored by conventional MFC-MRD.
MFC-LSC-positivity within 60 days pre HCT was highly prognostic for early disease progression, with 1-year cumulative incidence of relapse (CIR) of 72% for MFC-LSC-positive vs 19% for MFC-LSC-negative patients (hazard ratio (HR) 11.9; P o0.001), 1-year relapse-free survival (RFS) of 10% for MFC-LSC-positive vs 60% for MFC-LSC-negative patients (HR 5.84; P o0.001) ( Figure 1a ) and, in addition, appeared to be associated with a higher risk of early death with 1-year overall survival (OS) estimates of 46% for MFC-LSC-positive vs 66% for MFC-LSC-negative patients (HR 3.39; Po 0.01). When analysis included patients with samples sent between 60 and 90 days pre HCT, MFC-LSC-positivity remained prognostic for CIR, RFS and OS (Supplementary Results, Supplementary Table 1 ).
MFC-MRD-positivity within 60 days pre HCT was also associated with early disease progression consistent with previous studies, but appeared less prognostic than MFC-LSC (1-year CIR, 55% for MFC-MRD-positive vs 13% for MFC-MRD-negative patients (HR 3.86; P o0.01); 1-year RFS, 33% for MFC-MRD-positive vs 66% for MFC-MRD-negative patients (HR 2.27; P = 0.03) ( Figure 1b , also Supplementary Results, Supplementary Table 1 ).
To ascertain whether MFC-LSC and/or MFC-MRD were more predictive in patients undergoing RIC, we excluded the small number of patients undergoing MAC from the analysis of outcome. Detectable MFC-LSC pre HCT remained a stronger predictor of poor early outcome than MFC-MRD. All but one of the RIC patients who were MFC-LSC positive pre HCT had relapsed and/or died by 240 days from the time of transplant Supplementary Table 1 ).
MFC-LSC-positivity was more frequent in the adverse-risk cytogenetic subgroup (47% adverse risk vs 12% favourable/ intermediate (including FLT3-mutated); P = 0.003), with similar results for MFC-MRD ([74% adverse risk vs 39% favourable/ intermediate; P = 0.01). We therefore tested the relevance of MFC-LSC as a pre-transplant prognostic factor in a multivariate analysis that included MRD status, as well as cytogenetic risk Table 2 ). Post-transplant MRD monitoring may predict subsequent relapse and therefore aid targeted interventions. This is of particular relevance to recipients of RIC allografts given their higher relapse risk, but there has been little published data.
We examined the outcome of patients with MFC-LSC-or MFC-MRD-positivity detected post-HCT (while in morphological CR) (characteristics summarised in Supplementary Results, Supplementary Table 3 ). The cumulative incidences of MFC-MRD-and MFC-LSC-positivity post-HCT were 33% (23/69) and 17% (16/92), respectively, for those patients with sample data, with a median interval from HCT to detection of 105 days (range 38-339) for MFC-MRD and 102 days (range 38-368) for MFC-LSC.
MFC-MRD-positivity post-HCT was detected in 76% (19/25) of relapsed patients compared with 4% (3/76) of patients who had not relapsed at the time of analysis (P≪0.01). MFC-LSCs were detectable prior to 60% (15/25) of relapses vs 1% (1/76) in non-relapsed patients (P≪0.01). Three out of 25 relapses were within 100 days; all these were patients who were positive for both MFC-LSC and MFC-MRD pre HCT (Supplementary Results, Supplementary Table 4 ).
The high relapse rate of patients with MFC-MRD or MFC-LSC detected post-HCT (83% for MFC-MRD, 94% for MFC-LSC) not surprisingly resulted in a significantly poorer RFS and OS (Figures  1c and f) . Median time to progression (relapse or death) of these patients from detection of post-HCT MFC-MRD and MFC-LSC was 53 days (range 29-94 days) and 48 days (range 13-94 days), respectively. One patient was MFC-LSC-positive 2 months before MFC-MRD was detected.
Donor chimerism has been used as a surrogate marker of relapsing AML post HCT to guide post-HCT immunotherapy. In this cohort, 48% (12/25) of relapses occurred in patients who Supplementary Table 4 ). These results, although limited by small numbers, suggest that D90 chimerism or progressive MDC without evidence of post-HCT MFC-MRD/MFC-LSC is poorly predictive of early relapse, at least in RIC-HCT. This is unlikely to result from pre-emptive DLIs in this cohort as most relapses (21/25) occurred by 11 months post transplant, but only three patients (of which one was MFC-MRDpositive) received DLI within this time period.
The immunophenotypic heterogeneity of AML blasts with potential LSC activity has been defined functionally by xenotransplant models. 7, 10, 11 Our results provide clinical evidence for this since abnormal expansion of LMPP-like MFC-LSCs, although present in~80% of CD34+AML at diagnosis, did not precede all relapses. However, measurement of this MFC-LSC population is clinically applicable and adds valuable additional pre-transplant prognostic information to MFC-MRD, identifying a subset of patients with particularly poor early outcomes. This suggests that LSC detected by LMPP-like expansion are potentially more resistant to treatments, including standard RI conditioning, than LSC in other AML blast subsets, such as LSC from more mature AML progenitors. It would be valuable to test whether these MFC-LSC-positive patients would benefit from further anti-leukaemic therapy before HCT or more intensive conditioning.
Post transplant, MRD was strongly associated with relapse and reduced survival with an interval between MRD positivity and relapse, which may, in some patients, allow targeted manipulation of immunosuppression, pre-emptive DLI or pharmacological interventions 12 when disease burden is lower. Expansion of the LSC population appears a more-sensitive biomarker of relapse than standard MRD for some patients, but this may vary according to the kinetics of leukaemic proliferation from LSC and any GVL effect on LSC. It is as yet uncertain whether the chemoresistant properties of LSC are relevant to GVL resistance, so tracking the impact of GVL on the LMPP-like LSC compartment merits further investigation, particularly as changes in the bulk leukaemic population (detected by standard MRD), such as acquired genomic abnormalities 13, 14 reducing GVL, may be more important to leukaemia progression post transplant. It will be interesting to evaluate whether strategies such as epigenetic manipulation of the alloreactive response using azacitidine and lenalidomide can overcome persisting LMPP-like LSCs or potential reduced immunogenicity 15 of any post-transplant-emerging leukaemic populations in allografted AML patients.
